SCHEMBL2802165

SCHEMBL2802165

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3ccc(F)c(C)c3)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
EGLN1 Q9GZT9 1/20 0.38
PDE4B Q07343 2/20 0.38
SCN9A Q15858 3/20 0.37
FASN P49327 1/20 0.37
F11 P03951 1/20 0.36
IDO1 P14902 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
NFKB1 P19838 1/20 0.36
HTT P42858 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
SPR P35270 2/20 0.35
KMT2A Q03164 1/20 0.35
EPHA2 P29317 1/20 0.35
GSK3A P49840 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803140 0.94 FASN (0.39) ALDH1A1EGLN1PDE4BFASNSMN1; SMN2
SCHEMBL2801661 0.90 PDE4B (0.41) ALDH1A1EGLN1PDE4BFASNF11
SCHEMBL2800042 0.89 PDE4B (0.43) ALDH1A1EGLN1PDE4BFASNF11
SCHEMBL2802494 0.89 DRD2 (0.42) ALDH1A1PDE4BFASNSMN1; SMN2NPC1
SCHEMBL2800842 0.88 ALDH1A1 (0.38) ALDH1A1EGLN1SCN9AFASNF11
SCHEMBL2802820 0.87 ALDH1A1 (0.42) ALDH1A1EGLN1PDE4BF11IDO1
SCHEMBL2803213 0.87 NPC1 (0.40) ALDH1A1PDE4BFASNF11NPC1
SCHEMBL2800033 0.87 ALDH1A1 (0.43) ALDH1A1EGLN1SCN9AFASNF11
SCHEMBL2802799 0.87 ALDH1A1 (0.40) ALDH1A1EGLN1SCN9AFASNSMN1; SMN2
SCHEMBL2799384 0.87 NPC1 (0.38) ALDH1A1EGLN1PDE4BFASNF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 ALDH1A1 243/4885EGLN1 1967/4885PDE4B 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.